August 18th, 2025: FDA Flags Rising Safety Concerns Over Compounded and Counterfeit Ozempic and GLP-1 Drugs The FDA has issued a new warning highlighting the dangers of unapproved and compounded GLP-1 receptor agonists, including versions of semaglutidethe active ingredient in Ozempic and Wegovy
The most commonly reported effects include injection site reactions (redness, mild swelling, itching), joint pain or stiffness, numbness or tingling in the extremities (paresthesia), headaches, and mild fluid retention
[10] An earlier pilot from the same research group found oligofructose promoted satiety and reduced energy intake, [11] and a one-year trial of increased fermentable wheat fiber raised GLP-1 in adults with elevated insulin
It has the same active ingredient as Ozempic
Telehealth platforms like Doctronic.ai are revolutionizing how patients receive care